FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Koenig Sheldon L.                            |  |  |   |  |   | 2. Issuer Name and Ticker or Trading Symbol  Esperion Therapeutics, Inc. [ ESPR ] |     |                       |                 |  |                    |  |                       |                      | k all app<br>Direc                       | ionship of Reportin<br>all applicable)<br>Director  |   | 10% O  | wner  |
|--|--|--|---|--|---|---|-----|-----------------------|-----------------|--|--------------------|--|-----------------------|----------------------|--|---|---|--|---|
| (Last) (First) (Middle) C/O ESPERION THERAPEUTICS, INC. 3891 RANCHERO DRIVE, SUITE 150 |  |  |   |  | 3. Date of Earliest Transaction (Month/Day/Year) 03/07/2023 |   |     |                       |                 |  |                    |  |                       | X                    | Office<br>below                          | ,   | title Other (s<br>below)<br>dent and CEO                          |  | specify   |
| (Street) ANN ARBOR MI 48108 (City) (State) (Zip)                                       |  |  |   |  | 4. If Amendment, Date of Original Filed (Month/Day/Year)    |   |     |                       |                 |  |                    |  | 6. Indi<br>Line)<br>X | ′                    |  |   |   |  |   |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned       |  |  |   |  |   |   |     |                       |                 |  |                    |  |                       |                      |  |   |   |  |   |
| 1. Title of Security (Instr. 3)  2. Transacting Date (Month/Day)                       |  |  |   |  |   | Execution   |     | Date,                 | Transaction Di  |  |                    | Securities Acquired (A<br>isposed Of (D) (Instr. 3,                          |                       | 4 and Secur<br>Benef |  | cially<br>I Following   | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) |  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|  |  |  |   |  |   |   |     | Code                  | v               | Amount   | (A) or<br>(D) Pr   |  | rice                  | Transa               | Transaction(s)<br>(Instr. 3 and 4)       |   |   | (111311.4)   |   |
| Common Stock 03/07/2   |  |  |   |  | 2023  | 023   |     |                       | S               |  | 5,441(1)           | I  | ) \$                  | 5.056                | 56 194,815 <sup>(2)</sup>                |   |   | D  |   |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |  |   |  |   |   |     |                       |                 |  |                    |  |                       |                      |  |   |   |  |   |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                                    | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) |  | 4.<br>Transaction<br>Code (Instr.<br>8)                     |   | of  | r<br>osed<br>(1. 3, 4 | Expirat         | 6. Date Exercisal<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of Securities Underlying Derivative Security (I 3 and 4) |                       | Dei<br>Sec<br>(Ins   | Price of<br>ivative<br>curity<br>str. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | y   | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>t (Instr. 4)                           |
|  |  |  |   |  | Code  | v   | (A) | (D)                   | Date<br>Exercis | sable  | Expiration<br>Date | Title  | or<br>Numb<br>of      | er                   |  |   |   |  |   |

## **Explanation of Responses:**

- 1. Shares were sold to satisfy tax obligation on vested shares of performance-based restricted stock units.
- 2. Consists of 194,815 shares of common stock held, including 1,999 shares recently acquired in Esperion's Employee Stock Purchase Plan.

## Remarks:

/s/ Sheldon L. Koenig

03/08/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.